# BioSkryb Corporation

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bioskryb

- Industry: Biotechnology
- Headquarters: Durham, US
- Website: www.bioskryb.com
- Total disclosed funding: $12M
- Latest round: Seed (Jan 8, 2020)
- Investors on record: 2

## About

BioSkryb Corporation is a biotechnology company focused on single-cell genomic and transcriptomic analysis through innovative amplification technologies.Founded in 2018, BioSkryb Corporation is based in Durham, US, specializing in genomic and transcriptomic amplification solutions. The company was co-founded by Charles Gawad and Jay West. In January 2020, BioSkryb raised USD 11.5 mn in a SEED funding round led by Anzu Partners, which contributed to their total funding amount of USD 11.5 mn. The firm has participated in two significant investment deals to date, reflecting its strategic growth approach.BioSkryb Genomics specializes in advanced single-cell analysis technologies that focus on genomic and transcriptomic amplification. Their core offerings include the patented Primary Template-directed Amplification (PTA) and the ResolveOME multiomic analysis platform, enabling simultaneous genome and transcriptome amplification from individual cells. This technology addresses cellular heterogeneity challenges, offering insights into genomic variability crucial for understanding health and disease. BioSkryb serves diverse clients, including academic institutions and biotech firms in North America and Europe, with technologies like ResolveDNA achieving over 95% genome recovery and high sensitivity in single-cell genomics.BioSkryb Genomics operates a revenue model based on specialized genomic analysis services and products tailored to clients' needs. Client transactions typically occur through direct partnerships with academic and research entities, utilizing BioSkryb's proprietary technologies and bioinformatics platforms for custom genomic analysis and whole-genome amplification. The company’s pricing strategy reflects the advanced nature of their offerings, with clients investing in their technologies as part of their research budgets, suggesting a premium pricing model.BioSkryb plans to leverage its recent SEED funding of USD 11.5 mn raised in January 2020 to support the development of new products and expand its market presence. The company aims to enhance its genomic analysis offerings and explore new geographic markets beyond its current focus in North America and Europe, although specific regions and timelines for this expansion have not been disclosed.

## Funding rounds

- Seed, Jan 8, 2020, $12M — Wilson Sonsini Goodrich & Rosati, Anzu Partners

## Investors

- Wilson Sonsini Goodrich & Rosati — Seed
- Anzu Partners (https://capitalatlas.ai/funds/anzu-partners) — Seed